ECSP20003493A - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
ECSP20003493A
ECSP20003493A ECSENADI20203493A ECDI202003493A ECSP20003493A EC SP20003493 A ECSP20003493 A EC SP20003493A EC SENADI20203493 A ECSENADI20203493 A EC SENADI20203493A EC DI202003493 A ECDI202003493 A EC DI202003493A EC SP20003493 A ECSP20003493 A EC SP20003493A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
valsartan
atorvastatin
metformin
processes
Prior art date
Application number
ECSENADI20203493A
Other languages
English (en)
Inventor
Tony Yantao Zhang
Matthew Carl Allgeier
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP20003493A publication Critical patent/ECSP20003493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones sólidas de dosis fija oral de metformina, atorvastatina y valsartán, o sales aceptables desde el punto de vista farmacéutico de estos, procesos para la preparación de estas y el uso de la composición para tratar ciertas enfermedades.
ECSENADI20203493A 2017-07-17 2020-01-17 Composiciones farmacéuticas ECSP20003493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533332P 2017-07-17 2017-07-17
US201762538936P 2017-07-31 2017-07-31

Publications (1)

Publication Number Publication Date
ECSP20003493A true ECSP20003493A (es) 2020-08-31

Family

ID=63036446

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20203493A ECSP20003493A (es) 2017-07-17 2020-01-17 Composiciones farmacéuticas

Country Status (25)

Country Link
US (2) US11376223B2 (es)
EP (1) EP3654955B1 (es)
JP (1) JP6854384B2 (es)
KR (1) KR102409102B1 (es)
CN (1) CN110913843B (es)
AU (1) AU2018301924B2 (es)
BR (1) BR112019028278A2 (es)
CA (1) CA3069948C (es)
CL (1) CL2020000120A1 (es)
CO (1) CO2019015099A2 (es)
CR (1) CR20190577A (es)
DO (1) DOP2020000010A (es)
EC (1) ECSP20003493A (es)
ES (1) ES3032318T3 (es)
IL (1) IL272044A (es)
JO (2) JOP20200005B1 (es)
MA (1) MA49625A (es)
MY (1) MY198062A (es)
PE (1) PE20200174A1 (es)
PH (1) PH12020500120A1 (es)
SA (1) SA520410976B1 (es)
SG (1) SG11201912482WA (es)
UA (1) UA125535C2 (es)
WO (1) WO2019018155A1 (es)
ZA (1) ZA201908550B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018301924B2 (en) * 2017-07-17 2021-07-29 Eli Lilly And Company Pharmaceutical compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
WO1999047128A1 (en) 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
WO2004014427A1 (ja) * 2002-08-08 2004-02-19 Sankyo Company, Limited 血液脂質を低下させるための医薬組成物
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
CA2677623C (en) 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
US8574625B2 (en) * 2007-05-30 2013-11-05 Wockhardt Ltd. Tablet dosage form
MX2013000824A (es) 2010-07-21 2013-10-28 Nucitec Sa De Cv Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US9572784B2 (en) * 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US20150050333A1 (en) * 2012-03-30 2015-02-19 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
CN103054856A (zh) * 2012-12-30 2013-04-24 成都恒瑞制药有限公司 含有盐酸二甲双胍和阿托伐他汀钙的固体口服制剂
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR102013028883A2 (pt) 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
WO2016040462A2 (en) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
AU2018301924B2 (en) * 2017-07-17 2021-07-29 Eli Lilly And Company Pharmaceutical compositions

Also Published As

Publication number Publication date
AU2018301924B2 (en) 2021-07-29
MY198062A (en) 2023-07-31
US11918692B2 (en) 2024-03-05
JP2020527147A (ja) 2020-09-03
CA3069948A1 (en) 2019-01-24
UA125535C2 (uk) 2022-04-13
CR20190577A (es) 2020-01-29
US20220287978A1 (en) 2022-09-15
ES3032318T3 (en) 2025-07-17
EP3654955C0 (en) 2025-05-07
US11376223B2 (en) 2022-07-05
CA3069948C (en) 2022-05-17
US20210137842A1 (en) 2021-05-13
AU2018301924A1 (en) 2019-12-19
SA520410976B1 (ar) 2023-03-23
JOP20200005B1 (ar) 2024-04-18
WO2019018155A1 (en) 2019-01-24
CO2019015099A2 (es) 2020-01-17
ZA201908550B (en) 2024-06-26
CN110913843A (zh) 2020-03-24
KR102409102B1 (ko) 2022-06-16
JP6854384B2 (ja) 2021-04-07
JOP20200005A1 (ar) 2020-01-14
MA49625A (fr) 2020-05-27
SG11201912482WA (en) 2020-02-27
JOP20230099A1 (ar) 2023-05-04
KR20200015758A (ko) 2020-02-12
IL272044A (en) 2020-03-31
PE20200174A1 (es) 2020-01-24
NZ760868A (en) 2023-09-29
BR112019028278A2 (pt) 2020-07-14
CL2020000120A1 (es) 2020-07-17
CN110913843B (zh) 2022-09-13
DOP2020000010A (es) 2020-02-28
EP3654955A1 (en) 2020-05-27
EP3654955B1 (en) 2025-05-07
PH12020500120A1 (en) 2020-09-28

Similar Documents

Publication Publication Date Title
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
UY36124A (es) Derivados de carboxamida
MX2018003930A (es) Inhibidores de calicreína plasmática humana.
EA201692298A1 (ru) Производные карбоксамидов
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
DOP2020000010A (es) Composiciones farmacéuticas
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA201992754A1 (ru) Фармацевтические композиции
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
WO2020018034A3 (en) Oral pharmaceutical compositions comprising dpp-4 inhibitor